These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 17900304)

  • 1. The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers.
    Iborra S; Abánades DR; Parody N; Carrión J; Risueño RM; Pineda MA; Bonay P; Alonso C; Soto M
    Clin Exp Immunol; 2007 Nov; 150(2):375-85. PubMed ID: 17900304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.
    Soto M; Corvo L; Garde E; Ramírez L; Iniesta V; Bonay P; Gómez-Nieto C; González VM; Martín ME; Alonso C; Coelho EA; Barral A; Barral-Netto M; Iborra S
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003751. PubMed ID: 25955652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.
    Ramirez L; Corvo L; Duarte MC; Chávez-Fumagalli MA; Valadares DG; Santos DM; de Oliveira CI; Escutia MR; Alonso C; Bonay P; Tavares CA; Coelho EA; Soto M
    Parasit Vectors; 2014 Jan; 7():3. PubMed ID: 24382098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice.
    Iborra S; Parody N; Abánades DR; Bonay P; Prates D; Novais FO; Barral-Netto M; Alonso C; Soto M
    Microbes Infect; 2008; 10(10-11):1133-41. PubMed ID: 18603012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge.
    Ramírez L; Iborra S; Cortés J; Bonay P; Alonso C; Barral-Netto M; Soto M
    J Biomed Biotechnol; 2010; 2010():181690. PubMed ID: 20145701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice.
    Badiee A; Jaafari MR; Samiei A; Soroush D; Khamesipour A
    Clin Vaccine Immunol; 2008 Apr; 15(4):668-74. PubMed ID: 18235040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection.
    Parody N; Soto M; Requena JM; Alonso C
    Parasite Immunol; 2004; 26(6-7):283-93. PubMed ID: 15541032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
    Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Leishmania infantum acidic ribosomal protein LiP2a induces a prominent humoral response in vivo and stimulates cell proliferation in vitro and interferon-gamma (IFN-gamma) production by murine splenocytes.
    Soto M; Alonso C; Requena JM
    Clin Exp Immunol; 2000 Nov; 122(2):212-8. PubMed ID: 11091277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
    Ramírez L; Santos DM; Souza AP; Coelho EA; Barral A; Alonso C; Escutia MR; Bonay P; de Oliveira CI; Soto M
    Vaccine; 2013 Feb; 31(9):1312-9. PubMed ID: 23313653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
    Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
    Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
    Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
    J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.
    Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P
    Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitosan Nanoparticles Loaded with Whole and Soluble Leishmania Antigens, and Evaluation of Their Immunogenecity in a Mouse Model of Leishmaniasis.
    Hojatizade M; Soleymani M; Tafaghodi M; Badiee A; Chavoshian O; Jaafari MR
    Iran J Immunol; 2018 Dec; 15(4):281-293. PubMed ID: 30593742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.
    Tonui WK; Mejia JS; Hochberg L; Mbow ML; Ryan JR; Chan AS; Martin SK; Titus RG
    Infect Immun; 2004 Oct; 72(10):5654-61. PubMed ID: 15385463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Assessment of Induced Immune Responses Following Intramuscular Immunization with Fusion and Cocktail of LeIF, LACK and TSA Genes Against Cutaneous Leishmaniasis in BALB/c Mice.
    Maspi N; Ghaffarifar F; Sharifi Z; Dalimi A; Dayer MS
    Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):55-64. PubMed ID: 28779346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
    Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
    J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.